The objective of this multicenter clinical trial is to determine if hydroxyurea therapy is effective in the prevention of the onset of chronic end organ damage as determined by surrogate markers in pediatric patients with sickle cell anemia.  This clinical trial involves the cooperation of pediatric Clinical Sites with expertise in treating sickle cell anemia, and a coordinating center which oversees drug distribution, central laboratory functions, and data collection.